$4.620
-0.237 (-5.13%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
WHWK Prediction & Forecast by Similar Chart Analysis
Alphio's WHWK stock price prediction model matches the current Whitehawk Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $4.72 (+2.12%). The 1-week path is $4.72 (+2.25%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Whitehawk Therapeutics Inc Stock?
Whitehawk Therapeutics appears to be a good buy right now due to its current price of $4.62, which is significantly lower than the analyst price target of $6.5, suggesting a potential upside of 40%. Additionally, the company has recently secured $87.5 million in PIPE financing, which will extend its cash runway into the second half of 2028, supporting its growth in the oncology market. However, the main risk is its negative earnings per share (EPS) of -0.32 reported for the last quarter, indicating ongoing financial challenges.
WHWK stock price ended at $4.62 on Friday, after losing -5.13%
Whitehawk Therapeutics Inc (WHWK) last closed at $4.62, losing -5.13%. These facts feed the 1-day and 1-week WHWK price prediction above.
Forecast Drivers
Whitehawk Therapeutics Inc (WHWK) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bullish
Similar Chart Patterns
Stocks whose recent price path most closely matches WHWK, ranked by similarity.
Seasonality analysis for WHWK
Historically the probability of a positive August return for WHWK is 31.75%. March offers the highest probability of a positive month at 61.90%, while September is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.